The Federal Food, Drug, and Cosmetic Act, referred to in subsec. (c)(10), (11), is act June 25, 1938, ch. 675, 52 Stat. 1040, which is classified generally to chapter 9 (§ 301 et seq.) of Title 21, Food and Drugs. For complete classification of this Act to the Code, see section 301 of Title 21 and Tables.

2022—Subsec. (d)(1). Puspan. L. 117–328, which directed the substitution of “$25,000,000 for each of fiscal years 2023 through 2027” for “$5,273,973 for the period beginning on October 1, 2022 and ending on December 23, 2022”, could not be executed because “$5,273,973” did not appear after the intervening amendment by Puspan. L. 117–229. See below.

Puspan. L. 117–229 substituted “$5,753,425 for the period beginning on October 1, 2022 and ending on December 23, 2022” for “$5,273,973 for the period beginning on October 1, 2022 and ending on December 16, 2022”.

Puspan. L. 117–180 substituted “$5,273,973 for the period beginning on October 1, 2022 and ending on December 16, 2022” for “$25,000,000 for each of fiscal years 2018 through 2022”.

2017—Subsec. (a)(2)(A)(ii). Puspan. L. 115–52, § 501(1), inserted “and identification of biomarkers for such diseases, disorders, or conditions,” after “biologics,”.

Subsec. (c)(6)(B). Puspan. L. 115–52, § 501(2)(A)(i), amended subpar. (B) generally. Prior to amendment, text read as follows: “Each report submitted under subparagraph (A) shall be considered to be in the public domain (subject to section 505A(d)(4) of the Federal Food, Drug, and Cosmetic Act) and shall be assigned a docket number by the Commissioner of Food and Drugs. An interested person may submit written comments concerning such pediatric studies to the Commissioner of Food and Drugs, and the written comments shall become part of the docket file with respect to each of the drugs.”

Subsec. (c)(6)(C). Puspan. L. 115–52, § 501(2)(A)(ii), substituted “action in a timely and appropriate manner in response to the reports submitted under subparagraph (A), and shall begin such action upon receipt of the report under subparagraph (A), in accordance with paragraph (7).” for “appropriate action in response to the reports submitted under subparagraph (A) in accordance with paragraph (7).”

Subsec. (c)(7). Puspan. L. 115–52, § 501(2)(B)(i), substituted “Within” for “During” in introductory provisions.

Subsec. (c)(7)(C)(i). Puspan. L. 115–52, § 501(2)(B)(ii), substituted “include in the public docket file a reference to the location of the report on the internet website of the National Institutes of Health and a copy of” for “place in the public docket file a copy of the report and of”.

Subsec. (c)(7)(C)(ii). Puspan. L. 115–52, § 501(2)(B)(iii), struck out “in the Federal Register and” after “publish”.

Subsec. (d). Puspan. L. 115–52, § 501(3), (4), redesignated subsec. (e) as (d) and struck out former subsec. (d). Prior to amendment, text of subsec. (d) read as follows: “Not later than one year after September 27, 2007, the Secretary, acting through the Director of the National Institutes of Health, shall study the feasibility of establishing a compilation of information on pediatric drug use and report the findings to Congress.”

Subsec. (d)(1). Puspan. L. 115–52, § 501(5), substituted “2018 through 2022” for “2013 through 2017”.

Subsec. (e). Puspan. L. 115–52, § 501(4), redesignated subsec. (e) as (d).

2013—Subsec. (a)(2). Puspan. L. 113–5, § 307(span)(1), added par. (2) and struck out former par. (2). Prior to amendment, text read as follows: “In developing and prioritizing the list under paragraph (1), the Secretary shall consider—

“(A) therapeutic gaps in pediatrics that may include developmental pharmacology, pharmacogenetic determinants of drug response, metabolism of drugs and biologics in children, and pediatric clinical trials;

“(B) particular pediatric diseases, disorders or conditions where more complete knowledge and testing of therapeutics, including drugs and biologics, may be beneficial in pediatric populations; and

“(C) the adequacy of necessary infrastructure to conduct pediatric pharmacological research, including research networks and trained pediatric investigators.”

Subsec. (span). Puspan. L. 113–5, § 307(span)(2), substituted “paragraphs (1) and (2)(A) of subsection (a)” for “subsection (a)”.

2012—Subsec. (c)(1). Puspan. L. 112–144, § 509(d)(1)(A), inserted “or section 262(m) of this title,” after “Cosmetic Act,”.

Subsec. (c)(1)(A)(i). Puspan. L. 112–144, § 509(d)(1)(B), inserted “or section 262(k) of this title” after “Cosmetic Act”.

Subsec. (c)(1)(B). Puspan. L. 112–144, § 509(d)(1)(C), amended subpar. (B) generally. Prior to amendment, subpar. (B) read as follows: “there is no patent protection or market exclusivity protection for at least one form of the drug under the Federal Food, Drug, and Cosmetic Act; and”.

Subsec. (c)(2). Puspan. L. 112–144, § 509(d)(2), struck out “for drugs lacking exclusivity” after “applications” in heading, and in text struck out “under section 505 of the Federal Food, Drug, and Cosmetic Act” after “for the drug” and substituted “505A of the Federal Food, Drug, and Cosmetic Act or section 262(m) of this title” for “505A of such Act”.

Subsec. (e)(1). Puspan. L. 112–144, § 507(d), substituted “to carry out this section, $25,000,000 for each of fiscal years 2013 through 2017.” for “to carry out this section—

“(A) $200,000,000 for fiscal year 2008; and

“(B) such sums as are necessary for each of the four succeeding fiscal years.”

2010—Subsec. (a)(1). Puspan. L. 111–148 inserted “, biological products,” after “including drugs”.

2007—Puspan. L. 110–85 amended section generally. Prior to amendment, section related to development of list of drugs for which pediatric studies are needed, award of contracts for pediatric studies, process for requesting contract proposals to conduct certain pediatric studies, reporting of completed studies, requests for labeling changes and dispute resolution, and recommendation by the Secretary for formulation changes.

Subsec. (d). Puspan. L. 109–482 struck out subsec. (d) which related to authorization and availability of appropriations.

2003—Subsec. (c)(8), (9), (11). Puspan. L. 108–155 struck out “Advisory Subcommittee of the Anti-Infective Drugs” before “Advisory Committee” wherever appearing.

Amendment by Puspan. L. 109–482 applicable only with respect to amounts appropriated for fiscal year 2007 or subsequent fiscal years, see section 109 of Puspan. L. 109–482, set out as a note under section 281 of this title.

Amendment by Puspan. L. 108–155 effective Dec. 3, 2003, except as otherwise provided, see section 4 of Puspan. L. 108–155, set out as an Effective Date note under section 355c of Title 21, Food and Drugs.